The trend to return to baseline after an increase
of reactive T cells might be viewed as a transient response[11], associated to the immunosuppressive environment within a tumor mass. It turns the vaccination protocol into a tiresome activity given that multiples doses may be required to reach clinical efficacy. Conclusion Despite the small sample size, the results on the immune response and safety, combined with the results from other studies, are encouraging to the conduction of a clinical trial with multiples doses in patients with early lung cancer who underwent surgical treatment. The DC vaccine could be a hopeful adjuvant therapeutic modality for this group of patients because they do not AZD6738 present a gap to antigenic changes or a bulky disease. Acknowledgements and Funding
Funding: This study was supported Alvespimycin clinical trial by grant number 401327/05-1 from the National Council for Scientific and Technological Development (CNPq), Brazil. We thank the Department of Radiology of the Hospital Estadual Sumaré UNICAMP for support in carrying out the imaging methods. References 1. O’Mahony D, Kummar S, Gutierrez ME: Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol 2005, 23:9022–9028.PubMedCrossRef 2. Estimativa 2010 – Incidência de Câncer no Brasil – 2010 – INCA [http://www.inca.gov.br/estimativa/2010/index.asp?link=tabelaestados.asp&UF=BR] 3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceedings 2008, 83:584–594.PubMedCrossRef 4. Baleeiro RB, Anselmo LB, Soares FA, Pinto CAL, Ramos O, Gross JL, Haddad F, Younes RN, Tomiyoshi MY, Bergami-Santos PC, Barbuto JAM: High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-alpha in lung cancer. Cancer Immunol Immunother 2008, 57:1335–1345.PubMedCrossRef 5. Tabarkiewicz J, Rybojad P, Jablonka A, Rolinski J: CD1c+ and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer. Oncol Rep 2008, 19:237–243.PubMed 6. Detterbeck FC, Boffa
DJ, Tanoue LT: The new lung cancer staging system. Chest 2009, 136:260–271.PubMedCrossRef 7. Oken MM, Decitabine cell line Creech RH, Enzalutamide Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649–655.PubMedCrossRef 8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205–216.PubMedCrossRef 9. ctcaev3.pdf (objeto application/pdf) [http://ctep.cancer.